about
A lexicon for hepatocellular carcinoma surveillance ultrasonography: benign versus malignant lesionsMagnetization-tagged MRI is a simple method for predicting liver fibrosis.Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm.Dual-energy computed tomography arthrography of the shoulder joint using virtual monochromatic spectral imaging: optimal dose of contrast agent and monochromatic energy levelCorrelations of 3T DCE-MRI quantitative parameters with microvessel density in a human-colorectal-cancer xenograft mouse model.Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver diseaseQuantitative assessment of tumor responses after radiation therapy in a DLD-1 colon cancer mouse model using serial dynamic contrast-enhanced magnetic resonance imagingDiffusion-weighted MRI in intrahepatic bile duct adenoma arising from the cirrhotic liver.Added value of subtraction imaging in detecting arterial enhancement in small (<3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma.Single Hepatocellular Carcinoma: Preoperative MR Imaging to Predict Early Recurrence after Curative Resection.Curative Resection of Single Primary Hepatic Malignancy: Liver Imaging Reporting and Data System Category LR-M Portends a Worse Prognosis.Safety of Percutaneous Biopsy for Hepatic Angiosarcoma: Results of a Multicenter Korean Survey.Use of Imaging to Predict Complete Response of Colorectal Liver Metastases after Chemotherapy: MR Imaging versus CT Imaging.Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma.Usefulness of the tensile gallbladder fundus sign in the diagnosis of early acute cholecystitis.Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease.Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization.Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC.Optimisation of the MR protocol in pregnant women with suspected acute appendicitis.Use of Preoperative MRI to Select Candidates for Local Excision of MRI-Staged T1 and T2 Rectal Cancer: Can MRI Select Patients With N0 Tumors?[Inflammatory Hepatic Adenoma].CT-based abdominal aortic calcification score as a surrogate marker for predicting the presence of asymptomatic coronary artery disease.Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance.Prediction of the histopathological grade of hepatocellular carcinoma using qualitative diffusion-weighted, dynamic, and hepatobiliary phase MRI.A liver mass found after subtotal gastrectomy.T1 bright appendix sign to exclude acute appendicitis in pregnant women.Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trialFeasibility of radiation dose reduction with iterative reconstruction in abdominopelvic CT for patients with inappropriate arm positioningEvaluation of Early Response to Treatment of Hepatocellular Carcinoma with Yttrium-90 Radioembolization Using Quantitative Computed Tomography AnalysisAssessment of preoperative magnetic resonance imaging staging in patients with hepatocellular carcinoma undergoing resection compared with the seventh American Joint Committee on Cancer SystemPreoperative imaging evaluation of head and neck cancer: comparison of 2D spin-echo and 3D THRIVE MRI techniques with resected tumoursEfficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort studyLetter to the editorOptimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantationHow to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?Hepatobiliary versus Extracellular MRI Contrast Agents in Hepatocellular Carcinoma Detection: Hepatobiliary Phase Features in Relation to Disease-free SurvivalA proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significanceGadoxetic acid enhanced magnetic resonance imaging for prediction of the postoperative prognosis of intrahepatic mass-forming cholangiocarcinomaPitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS)
P50
Q30359302-E5B8FF36-55E5-4235-ABA1-871B46DA95B1Q30386029-75296A7A-23CE-4A11-84DE-19080B80C64AQ31108230-9D959E8A-4361-4B7E-9A06-E6C992388C04Q34592222-DDA50E1E-6BEA-432E-9BF1-7AC8C10DF83FQ35361001-594ED143-7181-4740-B2B3-378B2E93796CQ36181189-D525AEA9-EF31-45C9-9D11-8DD4D386DF52Q36347971-294209E9-E5DA-4C53-9694-C7D34EFC2EE8Q37168535-919CCA82-D03C-4B19-AC41-C539EAE5A126Q38058687-D5670C8C-CD30-4409-8A66-ECFD5AD7969BQ38370432-DEF0E576-B519-4993-8D20-8C45EC5B4F2FQ38704974-1004AE9D-62FD-46A9-B8EE-7749C7AC3282Q38808670-470DF434-2AB9-4B20-8560-71EA53C64FDDQ38887968-89548FD1-14EF-4B16-A8BB-79CA3E6693E8Q39259950-41BE0363-F9B7-440F-9C07-0072C95DE757Q44739048-358AB891-2B65-4A57-B39A-E3E6718FE659Q47326179-F3969EB5-EED5-4073-8883-ECFC66DE0804Q47603110-E3B5209C-A20F-4C8F-B7C3-FEAAA356DC3EQ48439487-0BBF8C81-1B02-4065-B025-8E99D7BC9F52Q48622310-EF539A62-0D82-4F6D-97F9-5F4949026D5EQ50143238-432DC726-ADDD-4CFE-BC61-8DDAB1D06425Q50858145-2DB1FA18-14B5-4C23-BE2E-A71D79D4A58DQ52990652-460677FF-1EF1-4768-B56F-1424124A286FQ53059723-BA23451F-80E1-4D4E-B0BB-66E54D90DE3CQ53081188-179DD569-7F81-49C8-AB26-BEA026135F60Q53097376-2F471760-7DF0-4900-B237-8CEFB03F6B50Q53600073-E2EA56AE-8852-414C-83C7-E56E8E17FC27Q54450501-2E85B244-0EC5-4543-AC64-29D88A68E807Q57210553-2FB2FE0F-088D-4F73-867C-ABC1421DDE69Q60924779-4D80D6F3-53F8-49AA-9353-8306EB2DE28AQ64115269-EA105A86-8346-49FB-825E-8DF7383BBAD2Q84590345-F9965696-74F2-4AD4-B8A8-FE238E5F9A9FQ87394515-8A78FEBD-CE3D-4786-8860-9B37268574C1Q89216394-4AD4FF9B-AE6F-49EF-BF83-ED0CF6929210Q89282637-FED63C11-FC63-4F1F-BDDB-3379A00FAD60Q89425004-B8B56AB9-AE23-41C1-BBE2-F10B4A2ABC04Q90528401-AFCF1C8D-1D60-4D5A-B512-992062D42377Q90585384-36E7F5B4-9ECE-4C41-8ED0-84EF5C462C94Q90601719-AFB08936-78CE-4E7E-8899-AA92578F2C44Q90757715-62FFE237-392E-44D7-B32F-F9296E435A9CQ90994423-31210C67-6FEF-4B92-B3AA-471AD591031C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Chansik An
@ast
Chansik An
@en
Chansik An
@es
Chansik An
@nl
Chansik An
@sl
type
label
Chansik An
@ast
Chansik An
@en
Chansik An
@es
Chansik An
@nl
Chansik An
@sl
prefLabel
Chansik An
@ast
Chansik An
@en
Chansik An
@es
Chansik An
@nl
Chansik An
@sl
P106
P1153
54381478200
P31
P496
0000-0002-0484-6658